Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 5/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PER2 | O15055 | 2/20 | 0.35 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893562 | 0.78 | PPARG (0.42) | PTGDR2PPARGAPEX1 | |
| SCHEMBL1885452 | 0.77 | TRPM8 (0.41) | PTGDR2PPARGL3MBTL1 | |
| SCHEMBL1887901 | 0.76 | PPARG (0.39) | PTGDR2PPARGAPEX1AKR1B10POLB | |
| SCHEMBL1889690 | 0.74 | PPARG (0.42) | PTGDR2PPARGAPEX1 | |
| SCHEMBL1889207 | 0.74 | SMN1; SMN2 (0.42) | PTGDR2PPARGL3MBTL1 | |
| SCHEMBL1887062 | 0.73 | HCRTR2 (0.37) | PTGDR2PPARGAPEX1POLBL3MBTL1 | |
| SCHEMBL1888892 | 0.73 | HCRTR2 (0.37) | PTGDR2PPARGAPEX1POLBL3MBTL1 | |
| SCHEMBL1890982 | 0.72 | APEX1 (0.49) | PTGDR2PPARGAPEX1AKR1B10TSHR | |
| SCHEMBL1888097 | 0.69 | PPARG (0.38) | PPARGPOLB | |
| SCHEMBL1887439 | 0.69 | PTGDR2 (0.47) | PTGDR2APEX1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH | 2011-05-05 | — | — | US | disclosed |
| US-7732618-B2 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2010-06-08 | — | — | US | disclosed |
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | HRH2, TBXA2R, PTGDR2 | PTGDR2 3/4885PPARG 123/4885APEX1 4106/4885 |
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | HRH2, TBXA2R, PTGDR2 | PTGDR2 3/4885PPARG 123/4885APEX1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.